

Reference number(s)
3504-H

SPECIALTY QUANTITY LIMIT PROGRAM

TAZVERIK (tazemetostat)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tazverik (tazemetostat) 200 mg tablets	240 per 30 days	Epithelioid Sarcoma: 800 mg twice daily Dose reduction: 600 mg to 200 mg orally twice daily

III. REFERENCES

1. Tazverik [package insert]. Cambridge, MA: Epizyme, Inc.; January 2020.

DOCUMENT HISTORY

Created: Specialty Clinical Development (JL) 01/2020
 Revised:
 Reviewed: CHART 02/06/2020
 External Review: 02/2020